Emily O. Dumas

997 total citations
28 papers, 503 citations indexed

About

Emily O. Dumas is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Emily O. Dumas has authored 28 papers receiving a total of 503 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hepatology, 10 papers in Infectious Diseases and 10 papers in Epidemiology. Recurrent topics in Emily O. Dumas's work include Hepatitis C virus research (18 papers), HIV/AIDS drug development and treatment (10 papers) and Hepatitis B Virus Studies (7 papers). Emily O. Dumas is often cited by papers focused on Hepatitis C virus research (18 papers), HIV/AIDS drug development and treatment (10 papers) and Hepatitis B Virus Studies (7 papers). Emily O. Dumas collaborates with scholars based in United States, Australia and Canada. Emily O. Dumas's co-authors include Gary M. Pollack, Thomas Podsadecki, Daniel E. Cohen, Xavier Forns, Barry Bernstein, Yi‐Lin Chiu, Jordan J. Feld, Nancy S. Shulman, Jennifer R. King and Wenjing Lü and has published in prestigious journals such as Gastroenterology, PLoS ONE and The Journal of Infectious Diseases.

In The Last Decade

Emily O. Dumas

28 papers receiving 491 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emily O. Dumas United States 12 244 183 83 73 65 28 503
Anna Mas Spain 6 142 0.6× 252 1.4× 14 0.2× 79 1.1× 173 2.7× 9 531
Jean Spénard Canada 15 143 0.6× 356 1.9× 32 0.4× 70 1.0× 69 1.1× 45 971
Dhvani Shah United States 11 75 0.3× 66 0.4× 11 0.1× 67 0.9× 43 0.7× 30 384
L Witzel Germany 21 133 0.5× 158 0.9× 7 0.1× 63 0.9× 65 1.0× 47 991
Saeed Mohammad United States 14 157 0.6× 132 0.7× 34 0.4× 39 0.5× 257 4.0× 65 784
Kazushige IINUMA Japan 10 152 0.6× 205 1.1× 24 0.3× 42 0.6× 104 1.6× 17 603
Megan Comerford United States 13 141 0.6× 255 1.4× 14 0.2× 60 0.8× 111 1.7× 26 517
René Bouw United Kingdom 9 22 0.1× 35 0.2× 24 0.3× 33 0.5× 36 0.6× 10 332
B Walton United Kingdom 12 39 0.2× 42 0.2× 35 0.4× 33 0.5× 43 0.7× 27 547
Jutta Miller United States 12 31 0.1× 42 0.2× 86 1.0× 15 0.2× 64 1.0× 20 483

Countries citing papers authored by Emily O. Dumas

Since Specialization
Citations

This map shows the geographic impact of Emily O. Dumas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily O. Dumas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily O. Dumas more than expected).

Fields of papers citing papers by Emily O. Dumas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily O. Dumas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily O. Dumas. The network helps show where Emily O. Dumas may publish in the future.

Co-authorship network of co-authors of Emily O. Dumas

This figure shows the co-authorship network connecting the top 25 collaborators of Emily O. Dumas. A scholar is included among the top collaborators of Emily O. Dumas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily O. Dumas. Emily O. Dumas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vasanthakumar, Aparna, J. Wade Davis, Manal Abunimeh, et al.. (2018). Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens. PLoS ONE. 13(5). e0198296–e0198296. 2 indexed citations
2.
3.
Holmes, Jacinta A., Arthur Y. Kim, Emily O. Dumas, et al.. (2018). Dynamic changes in innate immune responses during direct‐acting antiviral therapy for HCV infection. Journal of Viral Hepatitis. 26(3). 362–372. 14 indexed citations
4.
Welzel, Tania M., Tarik Asselah, Emily O. Dumas, et al.. (2017). Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. ˜The œLancet. Gastroenterology & hepatology. 2(7). 494–500. 33 indexed citations
5.
Agarwal, Kosh, Emily O. Dumas, Geoffrey W. McCaughan, et al.. (2017). Safety and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir and ± ribavirin in adult renal or liver transplant recipients with HCV infection (CORAL-I: cohorts 3–6). Journal of Hepatology. 66(1). S529–S530. 2 indexed citations
6.
Venuto, Charles S., Marianthi Markatou, Andrew J. Ocque, et al.. (2017). Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques. Antimicrobial Agents and Chemotherapy. 61(5). 4 indexed citations
7.
Polepally, Akshanth R., Jennifer R. King, Emily O. Dumas, et al.. (2016). Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers. Clinical Pharmacokinetics. 55(8). 1003–1014. 25 indexed citations
8.
Welzel, Tania M., Stefan Zeuzem, Emily O. Dumas, et al.. (2016). GARNET: High SVR Rates Following Eight-Week Treatment with Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir for Patients with HCV Genotype 1b Infection. The American Journal of Gastroenterology. 111. S388–S388. 1 indexed citations
9.
Alqahtani, Saleh A., Reşat Özaras, Isakov Va, et al.. (2016). Time to viral suppression is not related to achievement of SVR12 in HCV GT1‐infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. Journal of Viral Hepatitis. 24(4). 280–286. 8 indexed citations
10.
11.
12.
Waring, Jeffrey F., Emily O. Dumas, Sylvie Abel, et al.. (2015). Serum miR‐122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR‐122 in HCV‐infected subjects. Journal of Viral Hepatitis. 23(2). 96–104. 21 indexed citations
13.
Dumas, Emily O., Jeffrey Enejosa, Greg Ball, et al.. (2015). P1331 : Phase 3B studies to assess long-term clinical outcomes in HCV GT1-infected patients treated with ombitasvir/ paritaprevir/ritonavir and dasabuvir with or without ribavirin. Journal of Hepatology. 62. S855–S855. 2 indexed citations
14.
Teuscher, Nathan S., et al.. (2013). A food effect study and dose proportionality study to assess the pharmacokinetics and safety of bardoxolone methyl in healthy volunteers. Clinical Pharmacology in Drug Development. 3(4). 314–320. 6 indexed citations
15.
Lawitz, Eric, Andrew Campbell, Emily O. Dumas, et al.. (2012). 1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS. Journal of Hepatology. 56. S469–S470. 20 indexed citations
16.
Läwitz, E., F. Poordad, Andrew Campbell, et al.. (2012). 1210 ABT-267 COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12 WEEK ANTIVIRAL AND SAFETY ANALYSIS. Journal of Hepatology. 56. S480–S480. 20 indexed citations
17.
Ketteler, M., Kévin Martin, Mario Cozzolino, et al.. (2011). Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrology Dialysis Transplantation. 27(5). 1942–1949. 25 indexed citations
18.
Dumas, Emily O., et al.. (2011). 1204 PHARMACOKINETICS, SAFETY AND TOLERABILITY OF THE HCV NS5A INHIBITOR ABT-267 FOLLOWING SINGLE AND MULTIPLE DOSES IN HEALTHY ADULT VOLUNTEERS. Journal of Hepatology. 54. S475–S476. 19 indexed citations
19.
Dumas, Emily O., Walid M. Awni, Darrel P. Cohen, et al.. (2010). 747 PHARMACOKINETICS OF THE HCV POLYMERASE INHIBITOR ABT-072 FOLLOWING SINGLE AND MULTIPLE DOSING IN HEALTHY ADULT VOLUNTEERS. Journal of Hepatology. 52. S291–S291. 2 indexed citations
20.
Dumas, Emily O. & Gary M. Pollack. (2008). Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective. The AAPS Journal. 10(4). 537–51. 197 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Mas Breakdown of academic impact, for papers by Jean Spénard Breakdown of academic impact, for papers by Dhvani Shah Breakdown of academic impact, for papers by L Witzel Breakdown of academic impact, for papers by Saeed Mohammad Breakdown of academic impact, for papers by Kazushige IINUMA Breakdown of academic impact, for papers by Megan Comerford Breakdown of academic impact, for papers by René Bouw Breakdown of academic impact, for papers by B Walton Breakdown of academic impact, for papers by Jutta Miller
Rankless by CCL
2026